Occupational Asthma Reference
    
    
 
  | Burge PS, Efthimiou J, TurnerWarwick M, Nelmes PT,
    Double-blind trials of inhaled beclomethasone diproprionate and fluocortin butyl ester in allergen-induced immediate and late asthmatic reactions,
    Clin Allergy,
    1982;12:523-531, | 
 
 |  | 
 
	Keywords: beclomethasone, immediate reaction, late reaction, ch, fluocortin butyl esther
 	
	
 
	
 
	
					Known Authors
					
  	
 If you would like to become a known author and have your picture displayed along with your papers then please get in touch from the contact page. Known authors can choose to receive emails when their papers receive comments.
 
 
 
					Abstract
 
					
					
					The blocking effects of inhaled beclomethasone dipropionate (BDP) and fluocortin butyl ester (FCB) on the immediate and late asthmatic reactions induced by inhaled allergen were studied in two trials. In the first, a double-blind cross-over trial compared BDP (800 micrograms daily as powder) with FCB 8 mg daily (1:20 by wt.-Formulation 1). The second trial was identical in design and compared FCB 8 mg daily (1:20) with FCB 8 mg daily as Formulation 2 (1:40). Known BDP, 400 micrograms daily by pressurized aerosol was studied at the end of the second trial. Allergen provocation was performed before and after 7 days treatment with each drug, with a 2-week interval between each drug. Overall, a blocking index for the immediate reaction of greater than 50% was obtained in ten of twenty patients (50%) using BDP, and five of twenty-one (25%) using FCB (P less than 0.01). The late reaction was blocked in nine of eleven (82%) instances on BDP, and four of fourteen (33%) on FCB. Contrary to earlier reports, inhaled corticosteroid agents used for several days prior to bronchial challenge, were found to block both the immediate as well as the late reaction in many individuals
					
 		
					Full Text
 
	
     Full text of this reference not available
			
			
			
		
			Please Log In or Register to add the full text to this reference
			
	      
 
 
 				
				
			
				Comments
				
			 
 
 
 
 
 
 
	
 Please sign in or register to add your thoughts.